[Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (HIV infection, 2 to < 6 years) - Benefit assessment according to §35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004300
German
Original Title: Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamid (HIV-1-Infektion [Kinder ≥ 2 bis < 6 Jahre und ≥ 14 kg Koerpergewicht])
Details
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • HIV Infections
  • Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
  • Tenofovir
  • Cobicistat
  • Anti-HIV Agents
  • Emtricitabine
  • HIV Integrase Inhibitors
Keywords
  • Elvitegravir
  • Cobicistat
  • Emtricitabine
  • Tenofovir Alafenamide
  • HIV Infections
  • Child
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.